The brain-penetrant oral selective estrogen receptor degrader SIM0270 exhibited a favorable safety profile and early signals of antitumor activity in patients with estrogen receptor-positive, HER2-negative locally advanced or metastatic breast cancer, including those with ESR1 mutations.
Puma Biotechnology Presents Updated Findings from the TBCRC-022 Trial at the 2022 San Antonio Breast Cancer Symposium streetinsider.com - get the latest breaking news, showbiz & celebrity photos, sport news & rumours, viral videos and top stories from streetinsider.com Daily Mail and Mail on Sunday newspapers.
LOS ANGELES (BUSINESS WIRE) Puma Biotechnology, Inc. (NASDAQ: PBYI), a biopharmaceutical company, presented updated findings from the Translational Breast Cancer Research Consortium (TBCRC) Trial 022 at the ongoing 2022 San Antonio Breast Cancer Symposium in San Antonio, Texas. The poster (PD7-03), entitled “Nerat.
AMGEN PRESENTS NEW DATA FROM THORACIC ONCOLOGY PORTFOLIO AT WCLC21 mynewsdesk.com - get the latest breaking news, showbiz & celebrity photos, sport news & rumours, viral videos and top stories from mynewsdesk.com Daily Mail and Mail on Sunday newspapers.
Lumakras™ (sotorasib) helps control brain metastases europeanpharmaceuticalreview.com - get the latest breaking news, showbiz & celebrity photos, sport news & rumours, viral videos and top stories from europeanpharmaceuticalreview.com Daily Mail and Mail on Sunday newspapers.